comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 00:46:12 - browse：5

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： PhRMA sues HHS over Medicare drug price negotiation

hotspot

focus

explore

WSS

Listen: Biogen's messy board & Laronde's data problem

Pennsylvania man bitten on the head by bear during attack in his garage

Community addresses injustice for Long Island mothers

Restaurant meals are packed with calories, and we still keep eating them

Paxlovid rebound happens. Why and to whom are still a mystery

How CRISPR works, explained in two minutes

focus

comprehensive

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Heart attack and stroke risk calculators need revising

Pfizer's Covid pill remains 89% effective in final analysis, company says

Peter Hotez and the public health issue of online harassment

Google's generative AI to analyze medical images — and talk to docs

Medicare details structure of new drug price negotiation program

Doctors are clamoring for more clarity on Paxlovid prescribing

Medical leaders decry Supreme Court decision on affirmative action

These geoengineering technologies could help combat the climate crisis, scientists say

hotspot

Inside the fall of star MIT scientist David Sabatini

PhRMA sues HHS over Medicare drug price negotiation

Election results set back Medicaid expansion plans

St. Louis police protesters begin picking up checks in $4.9 million settlement

Tuberculosis patients need more than just free medication

With heat waves through August, officials warn of health risks

hotspot

focus

explore

focus